Sandra Kuzmich is a partner at the New York office of Frommer Lawrence & Haug LLP.
Dr. Kuzmich’s practice focuses on patent litigation, primarily relating to pharmaceutical litigation under the Hatch-Waxman Act.
Prior to joining Frommer Lawrence & Haug LLP, Dr. Kuzmich spent several years in the private pharmaceutical sector working in the areas of drug metabolism and pharmacokinetics.
Dr. Kuzmich received her undergraduate degree in chemistry from Douglass College, Rutgers University, after which she received a Ph.D. in pharmacology from Yale University in 1989. The focus of her Ph.D. thesis was the mechanisms of antiviral and antineoplastic activity of modified nucleosides.
Following her graduate studies she spent four years as a postdoctoral research associate at Fox Chase Cancer Center in Philadelphia where her research dealt with the mechanisms of anticancer drug resistance in colon cancer, with a focus on the role of the glutathione S-transferase family of enzymes in these resistance mechanisms.
